Mazumdar-Shaw’s Mission to Expand Access to Vital Drugs

Kiran Mazumdar-Shaw discusses Biocon's mission to make vital drugs affordable and accessible. She criticizes Western pharmaceutical companies for prioritizing high margins and high prices. She argues Biocon's high-volume, lower-price model can expand patient access while remaining profitable. - Kiran Mazumdar-Shaw describes the biotech industry as humanitarian and patient-focused. - She criticizes Western companies for emphasizing margins and high drug prices. - She says drugs should not be restricted to those who can afford them. - She explains Biocon's model is driven by high volume rather than high price. - She argues affordability does not mean lower profitability.